Inventiva price target lowered to $22 from $24 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Inventiva to $22 from $24 and keeps a Buy rating on the shares after the company voluntarily paused patient screening and randomization of the NATiV3 pivotal Phase 3 trial of lanifibranor. The firm notes that NATiV3 is expected to resume patient screening in about four to six weeks under an amended protocol.